Cantor Fitzgerald Maintains Overweight on TG Therapeutics, Lowers Price Target to $19

Cantor Fitzgerald maintains TG Therapeutics (NASDAQ:TGTX) with a Overweight and lowers the price target from $20 to $19.

Benzinga · 11/14/2019 18:28

Cantor Fitzgerald maintains TG Therapeutics (NASDAQ:TGTX) with a Overweight and lowers the price target from $20 to $19.